09/17/2026
Biosimilars stuck in a rut
A slew of brand-name biological drugs are due to lose patent protection in the next decade. But lower-cost versions are only in the pipeline for 1 out of 10, according to industry estimates.
Why it matters: That void in biosimilars could result in billions of dollars in unrealized savings for patients and the health system.
https://www.axios.com/2026/09/15/biosimilar-development-lagging-drug-costs